Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SINGAPORE EXCHANGE  >  Luye Pharma Group Ltd    LUYE   BMG5722Z1014

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

LUYE PHRM : Exercise Of The Call Option By Luye Biotech (Singapore) Pte Ltd Under The Investment Agreement To Acquire All The Shares Held By Biomedical Sciences Investment Fund Pte Ltd In The Issued Share Capital Of A-Bio Pharma Pte Ltd

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 12:35pm CEST

LUYE PHARMA GROUP LTD.

(INCORPORATED IN BERMUDA)

EXERCISE OF THE CALL OPTION BY LUYE BIOTECH (SINGAPORE) PTE LTD UNDER THE INVESTMENT AGREEMENT TO ACQUIRE ALL THE SHARES HELD BY BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD IN THE ISSUED SHARECAPITAL OF A-BIO PHARMA PTE LTD

Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company?s announcement dated

30 July 2010 in relation to the Strategic Investment in A-Bio Pharma Pte Ltd by Luye-Biotech

(Singapore) Pte Ltd.

The Board of Directors of Luye Pharma Group Ltd. (?Luye? or ?the Company?) is pleased to announce that Luye Biotech, a wholly-owned subsidiary of the Company, has exercised the Call Option under the Investment Agreement to acquire all of BMSIF?s shares comprising (i) one (1) ordinary share and (ii) 2,500,000 preference shares (Series B Preferred Shares) (collectively known as the ?Call Option Shares?) in A-Bio Pharma Pte Ltd (?A-Bio?) at a Option Consideration of S$2,750,000.

When the acquisition is completed, the Company will own 100% of the entire issued share capital of A-Bio through another wholly-owned subsidiary, Shandong Luye Pharmaceutical Co. Ltd.

The Option Consideration will funded by internal resources and is not expected to have any material impact on the net tangible assets per share and earnings per share of the Company for the current financial year ending 31 December 2011.

None of the Directors or controlling shareholders has any interest, directly or indirectly, in the transaction.

By Order of the Board

Liu Dianbo

Executive Chairman

Date: 25 July 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUYE PHARMA GROUP LTD
11:04a LUYE PHARMA : Change of name of principal share registrar and transfer office in..
03/31 LUYE PHARMA : Announces 2016 Annual Results
03/30 LUYE PHARMA : 2016 Net Up 18%
03/29 LUYE PHARMA : Appointment of non-executive director
03/29 LUYE PHARMA : Monthly Return of Equity Issuer on Movements in Securities for the..
03/29 LUYE PHARMA : Notice of board meeting
03/06 LUYE PHARMA : Obtains Clinical Trials Approval for Rivastigmine Multi-day Patch ..
03/02 LUYE PHARMA : Nodded for Clinical Test of Products
03/01 LUYE PHARMA : First Step towards Integrating European TDS Business
02/28 LUYE PHARMA : 3 products added to National medical catalogue
More news
Sector news : Generic Pharmaceuticals
05:59pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
02:37pDJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Generic Pharmaceuticals
Advertisement
Financials ( CNY)
Sales 2017 3 622 M
EBIT 2017 1 194 M
Net income 2017 1 066 M
Finance 2017 1 144 M
Yield 2017 0,81%
P/E ratio 2017 12,81
P/E ratio 2018 11,01
EV / Sales 2017 3,45x
EV / Sales 2018 2,96x
Capitalization 13 621 M
More Financials
Chart LUYE PHARMA GROUP LTD
Duration : Period :
Luye Pharma Group Ltd Technical Analysis Chart | LUYE | BMG5722Z1014 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 5,46  CNY
Spread / Average Target 33%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Dian Bo Liu Executive Chairman & Chief Executive Officer
Yuan Chong Liu Chief Financial Officer
You Xin Li Vice President, Head-Research & Development
Hui Xian Yuan Executive Director
Rong Bing Yang Vice Executive Chairman
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LUYE PHARMA GROUP LTD0.00%1 976
OTSUKA HOLDINGS CO LTD1.16%25 851
SUN PHARMACEUTICAL IND..2.63%23 798
ONO PHARMACEUTICAL CO...-11.73%11 970
SHANGHAI FOSUN PHARMAC..29.17%10 371
ASPEN PHARMACARE HOLDI..-2.28%9 487
More Results